As you may know, Dr. Richard Rudick, former Co-Principal Investigator of the Clinical and Translational Science Collaborative and director of the KL2 Training Program has accepted a prestigious offer in Boston with the pharmaceutical company, Biogen Idec.  We are pleased to announce the appointment of three highly experienced members of our leadership team that will provide strategic oversight to ensure a smooth transition in our program.

Serpil Erzurum, MD and Mark Chance, PhD will serve as Co-Principal Investigators to the CTSC. Serpil and Mark possess the strong leadership skills and demonstrated success in clinical research environments, participant-centered research, and translational technology that will complement the program.

Dr. Erzurum is the Director of the Cleveland Clinic Clinical Research Unit and Chair of the Department of Pathobiology and Joint Staff with the Respiratory Institute at Cleveland Clinic.  Serpil is a member of the Executive Committee and has been an engaged leader in clinical translational research since 2007.

Dr. Chance is the Director of the Translational Technologies Core and Vice Dean for Research at the CWRU School of Medicine.  He is also the Director of the Case Center for Proteomics and Bioinformatics and has focused much of his work on proteomics and research involving collaborations across multiple departments and disease areas. He is actively involved in fostering research collaborations with industry partners to accelerate translation and advance human health; in this role, he will advance one of the three main goals of the CTSC enunciated in our renewal application - to enhance T1 research. 

The National Institutes of Health (NIH) policy which states that on grant awards with a start date of July 1, 2013 and beyond it will delay award processing if publications arising from it are not in compliance with the NIH's public access policy. 

Currently, CWRU has 902 articles that are not fully compliant with the NIH Public Access Policy. Our institutional compliance rate is 85%. This is only a slight improvement over the past nine months.

We encourage researchers to contact the representatives from the Cleveland Health Sciences Library to enhance our institutional compliance with this mandate. Representatives are also available to conduct training sessions for departments or groups. For more information on training sessions or individual assistance, please contact Kathleen Blazar, MSLS, Assistant Director, at (216) 368-1361 or kcb2@case.edu. 

Join us in congratulating our 2014 CTSC Annual Pilot Award Recipients!

Amy Sheon is the founding Executive Director of the Urban Health Initiative. Her 25+ years' experience in government, academia and the non-profit sectors are being used to leverage the assets of CWRU in making an impact on the health of people living in Cleveland. Dr. Sheon's work has focused on creation of a new model of obesity surveillance using existing immunization registries, and she was instrumental in the establishment of three different centers at the University of Michigan, focused on clinical research, ethical issues in the life sciences, and on improving educational outcomes for disadvantaged youth. Dr. Sheon also worked at the National Institutes of Health on maternal-infant HIV transmission, HIV prevention studies, and cancer genetics. She earned an MPH at the University of Michigan and a Ph.D. from Johns Hopkins Bloomberg School of Public Health. 

The PRCHN Seminar Series is open to the public and takes place from Noon to 1:15 on the 2nd Wednesday of every month in the PRCHN Ground Floor Conference Room at the BioEnterprise Building, 11000 Cedar Avenue. Parking is available and a light lunch is served. 

The National Center of Regenerative Medicine (NCRM) is accepting proposals for funding of Demonstration Projects for the OH-Alive Innovator Platform: A Process and Manufacturing platform for Cell Therapy for the period November 1, 2014 - January 31, 2015. This is a new platform developed by the NCRM to accelerate new cell therapies to the clinic and involves the use of automated cell culture manufacturing equipment with design of experiments theory. 

To help you respond to this RFP, NCRM will be holding an Open House on June 16th at the new OH-Alive facility located at 10000 Cedar Avenue Room 3-138. 

Please RSVP to Michael Gilkey (meg14@case.edu) by June 12th as space is limited. For more information on this funding opportunity, visit the NCRM website. 

Key Deadlines: June 16, 2014, 5:00pm (CWRU Letter of Intent), August 1, 2014, 5:00pm EST (external application).

The Edward Mallinckrodt, Jr. Foundation is a private foundation that funds basic biomedical research in St Louis and throughout the United States. The mission of the Foundation is to support early stage investigators engaged in biomedical research that has the potential to significantly advance the understanding, diagnosis, or treatment of disease. 

Mallinckrodt Grants are competitively provided to investigators based on their proposals, selected from applicants on an annual basis. These awards are usually $60,000 per year for three years, provided an annual progress report is submitted and approved. Only two candidates from any institution are considered per cycle. From six to eight are chosen each cycle

For more information on this limited submission opportunity, visit the Office of Research Administration website. 

Key Deadlines: June 16, 2014 (CWRU internal application), July 15, 2014 (Institution formally nominates candidate), November 3, 2014 (Sponsor Deadline).

The Pew Scholars Program in the Biomedical Sciences provides funding to young investigators of outstanding promise in science relevant to the advancement of human health. The program makes grants to selected academic institutions to support the independent research of outstanding individuals who are in their first few years of their appointment at the assistant professor level. 

Number of Applications Allowed: One (see internal selection requirements below) Amount of Funding: $240,000 ($60,000 a year for four years) 

For more information on this limited submission opportunity, visit the Office of Research Administration website.